Exelixis Inc

Type: Company
Name: Exelixis Inc
Nationality: United States
Web Address: http://www.exelixis.com/
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Can You Handle Risk? With A Dozen Clinical Trials, Exelixis Has Strong Upside Potential

By Christopher F. Davis :As a PhD-level epidemiologist and market analyst, there is no sector more interesting to me than biotech . I have opined on several of these names in the past. Those of you who follow my work know that I search for companies that ... [Published BioPortfolio - Aug 19 2014]
First reported Jul 31 2014 - Updated Aug 01 2014 - 1 reports

Exelixis Announces Second Quarter 2014 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the quarter ended June 30, 2014. Q2 2014 Highlights and Recent Events Reported positive top-line results from coBRIM, the phase 3 pivotal trial ... [Published Business Wire Health News - Jul 31 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Exelixis' (EXEL) CEO Michael Morrissey on Q2 2014 Results - Earnings Call Transcript

OperatorGood day ladies and gentlemen and welcome to the Exelixis’ Second Quarter 2014 Financial Results Conference Call. My name is Whitey and I’ll be your operator for today. As a reminder this call is being recorded for replay purposes.I would now ... [Published Seeking Alpha - Aug 01 2014]
First reported Jul 31 2014 - Updated Aug 01 2014 - 1 reports

Exelixis (EXEL) Posts Quarterly Earnings, Beats Expectations By $0.01 EPS

Exelixis (NASDAQ:EXEL) announced its earnings results on Thursday. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.39) by $0.01, AmericanBankingNews.com reports. The company had revenue of $6.56 ... [Published American Banking News - Jul 31 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 1 reports

Cramer's Lightning Round - Exelixis Has 9 Lives (7/28/14)

By SA Editor Miriam Metzinger :Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday July 28.Bullish Calls: Exelixis (NASDAQ: EXEL ): "They have been beating the heck out of this. I think it is a decent spec. It has ... [Published Seeking Alpha - Jul 29 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Exelixis (EXEL) Scheduled to Post Quarterly Earnings on Thursday

Exelixis (NASDAQ:EXEL) is set to issue its Q214 quarterly earnings data on Thursday, July 31st. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $5.66 million for the quarter. Parties interested in participating in ... [Published American Banking News - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 1 reports

Lightning Round: GE, Air Lease & more

Fleetcor Technologies (FLT) : The company appears to be doing well, said Cramer. I'd take a look.Exelixis (EXEL): I think it's a decent spec, said Cramer. Year to date it's down, but I wouldn't give up on it.Air Lease (AL) : Investors have turned on the ... [Published CNBC - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 3 reports

Exelixis' Rumored Acquisition And Large Pipeline Offer Short-Term Gains, Long-Term Sustainability

By Shaun Zirnhelt :The current price provides a great entry point for investors in Exelixis, Inc. (NASDAQ: EXEL ). Since the company is not profitable the stock price moves closely with news, and events that impact future business prospects. The most ... [Published BioPortfolio - Jul 28 2014]
First reported Jul 15 2014 - Updated Jul 16 2014 - 4 reports

Physician Views: Is GlaxoSmithKline's BRAF/MEK combo making headway in V600 mutation-positive melanoma patients?

Although the clinical promise of cancer immunotherapies looks poised to see these products gain a dominant foothold in the oncology market for decades to come, developers of alternative cancer treatments will be hoping to carve out their own share of ... [Published FirstWord Pharma - Jul 16 2014]
First reported Jul 14 2014 - Updated Jul 15 2014 - 3 reports

Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape

Exelixis, Inc. ( EXEL ) was a big mover last session, as the company saw its shares rise 23% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the ... [Published Zacks.com - Jul 15 2014]
First reported Jul 14 2014 - Updated Jul 15 2014 - 3 reports

Bigger Moves Coming For Exelixis

It took a while for investor sentiment in Exelixis (EXEL) to recover after the company released less-than-stellar interim results for its Phase III Metastatic Castration-Resistant Prostate Cancer (mCRPC) trial for cabozantinib (COMET-1) back in March, ... [Published BioMedReports - Jul 15 2014]
First reported Jul 14 2014 - Updated Jul 15 2014 - 13 reports

Genentech, Exelixis have good results in melanoma therapy

Genentech and Exelixis said late Sunday that their still-in-testing therapy helped clinical trial subjects with melanoma live significantly longer without their disease worsening, a milestone that let the companies seek federal regulatory approval.The ... [Published San Francisco Chronicle - Jul 15 2014]

Quotes

Original Article: NEXT ARTICLE More From BioPortfolio on "Can You Handle Risk? With A Dozen Clinical Trials, Exelixis Has Strong Upside Potential"
Dr. Rastetter remarked, "Amir has been a great supporter of Receptos , both as an early investor and as a board member. We very much appreciate his leadership during a transformative period for Receptos and thank him for his service."
Original Article: NEXT ARTICLE More From BioPortfolio on "Exelixis' Rumored Acquisition And Large Pipeline Offer Short-Term Gains, Long-Term Sustainability"

More Content

All (162) | News (91) | Reports (0) | Blogs (64) | Audio/Video (0) | Fact Sheets (0) | Press Releases (7)
sort by: Date | Relevance
Can You Handle Risk? With A Dozen Clinical Tria... [Published BioPortfolio - Aug 19 2014]
Eisai files for US and EU approval of lenvatini... [Published Pharma Letter - Aug 18 2014]
Endometrial Cancer - Pipeline Review, H2 2014 -... [Published SBWire - Aug 13 2014]
Frontrunning: August 1 [Published Zero Hedge - Aug 01 2014]
Asia-Pacific circulating tumor cells (CTC) mark... [Published Live-PR.com - Aug 01 2014]
Exelixis' (EXEL) CEO Michael Morrissey on Q2 20... [Published Seeking Alpha - Aug 01 2014]
Exelixis (EXEL) Posts Quarterly Earnings, Beats... [Published American Banking News - Jul 31 2014]
Exelixis Announces Second Quarter 2014 Financia... [Published Business Wire Health News - Jul 31 2014]
West Coast Biotech Roundup: Amgen Layoffs, Aval... [Published BioPortfolio - Jul 31 2014]
Complete Response Letter from FDA, Positive Opi... [Published Financial Services - Jul 31 2014]
RECEPTOS : Announces Appointment of Mary Szela ... [Published 4 Traders - Jul 30 2014]
Exelixis (EXEL) Scheduled to Post Quarterly Ear... [Published American Banking News - Jul 30 2014]
Ziopharm: Pipeline Expansion And Data Updates T... [Published Seeking Alpha - Jul 29 2014]
Biotech Companies Release Quarterly Financials ... [Published Financial Services - Jul 29 2014]
Cramer's Lightning Round - Exelixis Has 9 Lives... [Published Seeking Alpha - Jul 29 2014]
Lightning Round: GE, Air Lease & more [Published CNBC - Jul 28 2014]
Exelixis' Rumored Acquisition And Large Pipelin... [Published BioPortfolio - Jul 28 2014]
Exelixis Up 6.6%, Shares Break Through Resistan... [Published Comtex SmarTrend - Jul 28 2014]
Exelixis Up 6.6%, Shares Break Through Resistan... [Published Individual.com - Jul 28 2014]
Is this Exelixis Stock's Worst Nightmare? [Published Motley Fool - Jul 22 2014]
Clinovo TechTrainings: Next Session of SAS and ... [Published PRWeb - Jul 22 2014]
SEC Filings, Positive Trial Results, Technical ... [Published Reuters - Jul 18 2014]
SEC Filings, Positive Trial Results, Technical ... [Published Financial Services - Jul 18 2014]
Exelixis, Inc., Analyst Report; The Upside Pote... [Published Bio-Medicine - Jul 18 2014]
Exelixis, Inc., Analyst Report; The Upside Pote... [Published TickerTech.com - Jul 17 2014]
Exelixis, Inc., Analyst Report; The Upside Pote... [Published PR Newswire: Financial Services - Jul 17 2014]
West Coast Biotech Roundup: Genentech, CareDx, ... [Published Xconomy - Jul 17 2014]
West Coast Biotech Roundup: Genentech, CareDx, ... [Published BioPortfolio - Jul 17 2014]
Exelixis to Release Second Quarter 2014 Financi... [Published BioPortfolio - Jul 16 2014]
Exelixis to Release Second Quarter 2014 Financi... [Published Business Wire Health News - Jul 16 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Frontrunning: August 1 [Published Zero Hedge - Aug 01 2014]
As we predicted yesterday , the "big" Gaza ceasefire lasted all of a few hours ( Reuters ) To Lift Sales, G.M. Turns to Discounts ( NYT ) Espirito Santo Family’s Swift Fall From Grace Jolts Portugal ( BBG ) Argentine Debt Feud Finds Much Fault, Few Fixes ...
Exelixis Announces Second Quarter 2014 Financia... [Published Business Wire Health News - Jul 31 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the quarter ended June 30, 2014. Q2 2014 Highlights and Recent Events Reported positive top-line results from coBRIM, the phase 3 pivotal trial ...
Exelixis, Inc., Analyst Report; The Upside Pote... [Published PR Newswire: Financial Services - Jul 17 2014]
NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company. EXEL developed two cancer treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). Both use small molecules as the active component. ...
Exelixis to Release Second Quarter 2014 Financi... [Published Business Wire Health News - Jul 16 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2014 financial results will be released on Thursday, July 31, 2014 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis ...
Critical Alerts For Exelixis, Rocket Fuel, Netf... [Published PR Newswire: Financial Services - Jul 15 2014]
CHICAGO, July 15, 2014 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXEL, FUEL, NFLX, JNJ, and ACHN.To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Complete Response Letter from FDA, Positive Opi... [Published Financial Services - Jul 31 2014]
Biotech Companies Release Quarterly Financials ... [Published Financial Services - Jul 29 2014]
SEC Filings, Positive Trial Results, Technical ... [Published Financial Services - Jul 18 2014]
Technical Data on Health Care Sector Equities -... [Published Financial Services - Jul 10 2014]
Technical Data on Biotech Stocks -- Research on... [Published Financial Services - May 06 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.